Leveraging preclinical prior information has the potential to enhance the efficiency of Phase I oncology trials if used appropriately. In this paper, a comparison of the meta-analytic predictive (MAP) prior approach and the power prior approach is undertaken i... ...

请注册登录后继续浏览